Xencor, Inc. (Nasdaq: XNCR), a clinical-stage biopharmaceutical company focused on developing engineered antibodies for treating cancer and other serious conditions, has announced the launch of an underwritten public offering of its common stock. Certain investors may choose to purchase pre-funded…
Ncardia, a leading human iPSC company, has announced the launch of a new panel of ready-to-use assays aimed at streamlining the screening and selection of therapeutic candidates, with a particular focus on neurodegenerative diseases. This innovative panel offers standardized, robust,…
enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company, announced its financial results for the third quarter ending July 31, 2024, along with a business update. The company’s lead investigational product, detalimogene voraplasmid (formerly known as EG-70), is currently…
Ascendis Pharma A/S (Nasdaq: ASND) has released its financial results for the second quarter, which ended on June 30, 2024, alongside a business update. “The recent FDA approval of YORVIPATH underscores our commitment to helping patients with hypoparathyroidism and other…
Eli Lilly and Company (NYSE: LLY) has announced positive results from two phase 3 clinical trials, QWINT-1 and QWINT-3, evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes. The trials assessed efsitora’s efficacy in individuals starting insulin…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the results from its Phase 3 PALISADE study, which investigated the efficacy of the drug plozasiran in patients with familial chylomicronemia syndrome (FCS). FCS is a rare and severe genetic condition that currently…
The NBI-‘568-SCZ2028 dose-finding study successfully met its primary endpoint with the once-daily 20 mg dose. This dose showed a significant and clinically meaningful reduction in the Positive and Negative Syndrome Scale (PANSS) total score at Week 6, achieving a placebo-adjusted…
Moderna, Inc. (NASDAQ) has announced the launch of its new awareness initiative, “Do It For You & Them,” aimed at boosting COVID-19 vaccination rates across the United States. This campaign is part of Moderna’s ongoing efforts to address the elevated…
CVS Pharmacy® (NYSE: CVS) has announced that the updated COVID-19 vaccines for the 2024-2025 season, along with flu vaccines, are now available at CVS Pharmacy and MinuteClinic® locations nationwide. Walk-ins are welcome, and the company’s digital vaccine scheduler has been…
Quantum-Si Incorporated (Nasdaq: QSI), known as “The Protein Sequencing Company™,” has announced key leadership appointments. Effective September 17, 2024, Todd Bennett will join the company as the new Chief Commercial Officer. Additionally, John Vieceli, Ph.D., has been named Chief Product…
The new report, “Pharmaceutical Processing and Packaging Equipment Market: Size, Share, Forecast, and Trends Analysis by Formulation, Secondary Packaging, and End-of-Line Packaging – Global Forecast to 2031,” is now available on ResearchAndMarkets.com. The global pharmaceutical processing and packaging equipment market…
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), a leader in interventional oncology specializing in the treatment of primary and metastatic liver cancers, has announced the publication of an independent study in the European Society for Medical Oncology’s journal…
